MX2023000661A - Métodos y composiciones para la eficiencia y especificidad de arn guía de crispr/cas9 frente a aislados de vih-1 genéticamente diferentes. - Google Patents

Métodos y composiciones para la eficiencia y especificidad de arn guía de crispr/cas9 frente a aislados de vih-1 genéticamente diferentes.

Info

Publication number
MX2023000661A
MX2023000661A MX2023000661A MX2023000661A MX2023000661A MX 2023000661 A MX2023000661 A MX 2023000661A MX 2023000661 A MX2023000661 A MX 2023000661A MX 2023000661 A MX2023000661 A MX 2023000661A MX 2023000661 A MX2023000661 A MX 2023000661A
Authority
MX
Mexico
Prior art keywords
seq
hiv
grnas
sequence
target
Prior art date
Application number
MX2023000661A
Other languages
English (en)
Inventor
Alexandra L Howell
Susan K Eszterhas
Matthew S Hayden
Original Assignee
Alexandra L Howell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexandra L Howell filed Critical Alexandra L Howell
Publication of MX2023000661A publication Critical patent/MX2023000661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se divulgan ARN guías (ARNg) que se unen específicamente a la secuencia 5' LTR del virus de la inmunodeficiencia humana-1 (VIH-1) que comprende TTGGATGGTGCTTCAAGTTA (SEQ ID NO: 1); se divulgan ARNg que se unen específicamente a la secuencia 5' LTR del VIH-1 que comprende CTACAAGGGACTTTCCGCTG (SEQ ID NO:2); se divulgan ARNg que se unen específicamente a la secuencia 5' LTR del VIH-1 que comprende TCTACAAGGGACTTTCCGCT (SEQ ID NO: 3); se divulgan secuencias de ácidos nucleicos que comprenden una secuencia de ácidos nucleicos que codifica uno o más ARNg, en donde dicho uno o más ARNg se hibrida con una secuencia diana en el VIH-1, en donde la secuencia diana se selecciona del grupo que consiste en las SEQ ID NO: 1, SEQ ID NO:2 y SEQ ID NO:3; se divulgan vectores que comprenden una secuencia de ácidos nucleicos que codifica uno o más ARNg, en donde el uno o más ARNg se hibrida con una secuencia diana en el VIH-1, en donde la secuencia diana se selecciona del grupo que consiste en las SEQ ID NO: 1, SEQ ID NO:2 y SEQ ID NO:3; se divulgan métodos para inhibir la función de una secuencia diana de ADN de VIH-1 en una célula o eliminar una secuencia diana de ADN de VIH-1 de un genoma celular que comprenden poner en contacto una célula que comprende un genoma celular y que contiene un genoma de VIH-1 que comprende una secuencia diana de ADN de VIH-1 integrada en el genoma celular con uno o más ARNg, o ácidos nucleicos que codifican dicho uno o más ARNg, y una proteína asociada a grupos de repeticiones palindrómicas cortas en intervalos regulares (cas), o secuencia de ácidos nucleicos que codifica una proteína cas, en donde el uno o más ARNg se hibrida de manera única con la secuencia diana de ADN de VIH-1, en donde la secuencia diana de ADN de VIH-1 se selecciona del grupo que consiste en las SEQ ID NO: 1, SEQ ID NO:2 y SEQ ID NO:3; inhibiendo de esta manera la función o presencia de la secuencia diana de ADN de VIH-1.
MX2023000661A 2020-07-13 2021-07-13 Métodos y composiciones para la eficiencia y especificidad de arn guía de crispr/cas9 frente a aislados de vih-1 genéticamente diferentes. MX2023000661A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063051212P 2020-07-13 2020-07-13
PCT/US2021/041385 WO2022015702A2 (en) 2020-07-13 2021-07-13 Methods and compositions for crispr/cas9 guide rna efficiency and specificity against genetically diverse hiv-1 isolates

Publications (1)

Publication Number Publication Date
MX2023000661A true MX2023000661A (es) 2023-07-03

Family

ID=79555854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000661A MX2023000661A (es) 2020-07-13 2021-07-13 Métodos y composiciones para la eficiencia y especificidad de arn guía de crispr/cas9 frente a aislados de vih-1 genéticamente diferentes.

Country Status (6)

Country Link
US (1) US20230313193A1 (es)
EP (1) EP4179120A2 (es)
JP (1) JP2023534968A (es)
CA (1) CA3185970A1 (es)
MX (1) MX2023000661A (es)
WO (1) WO2022015702A2 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908253C (en) * 2013-04-04 2024-01-09 Trustees Of Dartmouth College Compositions and methods for in vivo excision of hiv-1 proviral dna
CN106102781A (zh) * 2013-08-29 2016-11-09 英联邦高等教育***天普大学 用于hiv感染的rna指导的治疗的方法和组合物
WO2016086177A2 (en) * 2014-11-25 2016-06-02 Drexel University Compositions and methods for hiv quasi-species excision from hiv-1-infected patients

Also Published As

Publication number Publication date
EP4179120A2 (en) 2023-05-17
US20230313193A1 (en) 2023-10-05
WO2022015702A2 (en) 2022-01-20
WO2022015702A3 (en) 2022-02-17
CA3185970A1 (en) 2022-01-20
JP2023534968A (ja) 2023-08-15

Similar Documents

Publication Publication Date Title
KR101994953B1 (ko) 침입성 dna 바이러스에 대해 식물 내성을 강화하는 방법
Gualberto et al. Editing of the wheat cox III transcript: evidence for twelve C to U and one U to C conversions and for sequence similarities around editing sites
Bampi et al. The chaperoning and assistance roles of the HIV-1 nucleocapsid protein in proviral DNA synthesis and maintenance
Homann et al. Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1
RU2022103603A (ru) Направляемые нуклеиновыми кислотами нуклеазы
Yuki et al. Identification of genes for reverse transcriptase–like enzymes in two Drosophila retrotransposons, 412 and gypsy; a rapid detection method of reverse transcriptase genes using YXDD box probes
Böhnlein et al. Identification of a U5-specific sequence required for efficient polyadenylation within the human immunodeficiency virus long terminal repeat
JP2002272489A5 (es)
CN107151677B (zh) 基于CRISPR/Cas9多基因敲除低转染效率细胞系的方法
US5405775A (en) Retrons coding for hybrid DNA/RNA molecules
RU2019130498A (ru) Способ репликации или амплификации кольцевой днк
CN107245493B (zh) 一种表达受茶碱调控的适体核酶修饰型sgRNA的载体及应用
CN106282173A (zh) 克隆转基因生物中外源基因整合位点处侧翼序列的方法
JPH11513881A (ja) テンプレートおよびプライマーに基づく酵素的に切断可能なオリゴヌクレオチドの合成
MX2023000661A (es) Métodos y composiciones para la eficiencia y especificidad de arn guía de crispr/cas9 frente a aislados de vih-1 genéticamente diferentes.
CA2445700A1 (en) Protein involved in restoration of cytoplasmic male sterility to fertility and gene encoding the protein and gene
EP0593132A1 (en) Gene synthesis
Kyaw-Tanner et al. Quasispecies and naturally occurring superinfection in feline immunodeficiency virus infection
Kaushik et al. PNA targeting the PBS and A-loop sequences of HIV-1 genome destabilizes packaged tRNA3Lys in the virions and inhibits HIV-1 replication
AU2001279663A1 (en) Nucleotide sequences which code for the lysr2 gene
EP1217069A3 (en) Nucleotide sequences which code for the ilvE gene
Darlix et al. Analysis of the secondary and tertiary structures of Rous sarcoma virus RNA
WO2002022829A3 (en) Nucleotide sequences which code for the ppsa gene
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
CN111849983A (zh) 一种sgRNA及其应用